Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

OBJECTIVE: To test the hypothesis that treatment decisions (treatment with a PCSK9-mAb versus no treatment) are both more effective and more cost-effective when based on estimated lifetime benefit than when based on estimated risk reduction over 10 years. METHODS: A microsimulation model was constru...

Descripción completa

Detalles Bibliográficos
Autores principales: Berkelmans, Gijs F. N., Greving, Jacoba P., van der Graaf, Yolanda, Visseren, Frank L. J., Dorresteijn, Jannick A. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161238/
https://www.ncbi.nlm.nih.gov/pubmed/32318625
http://dx.doi.org/10.1186/s41512-020-00072-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161238/
https://www.ncbi.nlm.nih.gov/pubmed/32318625
http://dx.doi.org/10.1186/s41512-020-00072-5

Ejemplares similares